Skip to main content
Scott Kopetz on Muck Rack

Scott Kopetz

Houston
As seen in: Color Research & Application, Nature, Gut Journal, Taylor & Francis Online, Medscape, Cell Press, The Lancet, Healio, HemOnc Today, Molecular Cancer Research and
Colorectal cancer physician scientist, NCI Colon Task Force Chair, Professor, and Deputy Chair at The University of Texas, MD Anderson Cancer Center.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Scott

Contact Scott, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Spatial multi-omics landscape of colorectal cancer macro- and micrometastases

|
By Yang Liu, Akshaya Jadhav, Yuwen Pan, Jianlong Liao, Isha Khanduri, Yunhe Liu, Riham Katkhuda, Wei Lu, Kyung Serk Cho, Zhimin Tong, Tieling Zhou, Kangyu Lin, Baohua Sun, Mei Jiang, Sharia Hernandez, Patrick Brennan, Guangsheng Pei, Kai Yu, Yibo Dai, Tian Ren Chu, Fuduan Peng, Ling Xia, Youming Guo, Alicia Mejia, Sean Barnes, Ou Shi, Alaa Mohamed, Natalie Fowlkes, Timothy Newhook, Yun Shin Chun, Van Morris, David G. Menter, Dadi Jiang, John Paul Shen, Ryan Sun, Jean-Nicolas Vauthey, Ruoyan Li, Humam Kadara, Scott Kopetz, Linghua Wang, Dipen M. Maru, Saxon Rodriguez, Shreeya Indulkar, Luisa M. Solis Soto
| Cell Press Verified
Introduction While early detection through screening has significantly reduced the incidence of localized colorectal cancer (CRC),1 limited understanding of the biological mechanisms driving colorectal metastasis remains a major barrier to improving long-term survival.
Open in Who Shared Issue with article?

Insights from the ASCO Annual Meeting

|
By Scott Kopetz
| Oncology Learning Network Verified
Clinical Summary: Design/Population: Cohort 3 of the phase 3 BREAKWATER trial randomized 147 patients with previously untreated, BRAF V600E-mutant metastatic colorectal cancer and ECOG performance status 0–1 to receive encorafenib plus cetuximab and FOLFIRI (EC+FOLFIRI) or standard FOLFIRI-based therapy with or without bevacizumab.
Open in Who Shared Issue with article?

IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer

|
By Akash R Boda, Irfan N Bandey, Saikat Chowdhury, Sadhna Aggarwal, Venugopalareddy Mekala, Natalie Fowlkes, Amanda Anderson, Jason Roszik, Michael Curran, Van Morris, Scott Kopetz, Manisha Singh Verified
| Nature Verified
Abstract Pancreatic ductal adenocarcinoma (PDAC) has a poor survival rate and limited treatments. Agonistic CD40 antibodies are promising, but clinical trials have shown only modest efficacy and significant hepatotoxicity. We previously reported that IL-1 pathway blockade enhances CD40 agonist efficacy against melanoma by depleting polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs; CD11b+Ly6C+Ly6G+).
Open in Who Shared Issue with article?
See all 76 licensed articles (136 Total)